Business Description
Adlai Nortye Ltd
ISIN : US00704R1095
Share Class Description:
ANL: ADRDescription
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.12 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.4 | |||||
| Debt-to-EBITDA | -0.41 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.41 | |||||
| 9-Day RSI | 50.83 | |||||
| 14-Day RSI | 53.87 | |||||
| 6-1 Month Momentum % | 13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.01 | |||||
| Quick Ratio | 2.01 | |||||
| Cash Ratio | 1.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -368.16 | |||||
| ROA % | -93.13 | |||||
| ROIC % | -12.46 | |||||
| ROC (Joel Greenblatt) % | -1583.05 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 37.57 | |||||
| PB Ratio | 6.04 | |||||
| Price-to-Tangible-Book | 6.47 | |||||
| EV-to-EBIT | -5.28 | |||||
| EV-to-EBITDA | -5.36 | |||||
| EV-to-Revenue | 82.55 | |||||
| EV-to-FCF | -22.42 | |||||
| Price-to-Net-Current-Asset-Value | 10.16 | |||||
| Price-to-Net-Cash | 10.79 | |||||
| Earnings Yield (Greenblatt) % | -18.94 | |||||
| FCF Yield % | -3.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ANL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adlai Nortye Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5 | ||
| EPS (TTM) ($) | -2.125 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 53.87 | ||
| 14-Day ATR ($) | 1.267903 | ||
| 20-Day SMA ($) | 13.1245 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 7.1114 - 19.2999 | ||
| Shares Outstanding (Mil) | 36.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adlai Nortye Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adlai Nortye Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Adlai Nortye Ltd Frequently Asked Questions
What is Adlai Nortye Ltd(ANL)'s stock price today?
The current price of ANL is $13.92. The 52 week high of ANL is $19.30 and 52 week low is $7.11.
When is next earnings date of Adlai Nortye Ltd(ANL)?
The next earnings date of Adlai Nortye Ltd(ANL) is 2024-05-31 Est..
Does Adlai Nortye Ltd(ANL) pay dividends? If so, how much?
Adlai Nortye Ltd(ANL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers